Overview: Leverege is an Internet of Things (IoT) software company with a suite of cloud-based products that simplify and accelerate any IoT project.
Goal: Leverege aims to become the #1 destination for all things IoT. Learn. Build. Launch.
Pipeline: Currently working with numerous commercial companies in a number of verticals launching IoT projects for asset tracking, remote monitoring and control, energy management, security, and defense applications. Partner ecosystem is growing nicely and recently became technology partners of Google and AT&T. Anticipate increasing monthly recurring revenue associated with licensing of the cloud-based platform and sales of the accelerated IoT deployment package called Jumpstart.
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the closing of its underwritten public offering of 8,050,000 shares of its common stock at a public offering price of $11.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock. All of the shares in the offering were offered by GlycoMimetics. The aggregate gross proceeds to GlycoMimetics from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $92.6 million.
Over the past four years, 1,668 deals involving university spinout companies from across the globe attracted approximately $35.6 billion from 2013 to 2016, according to a new report from Global University Venturing. The report, however, highlights that global deals peaked in 2014 with 529 deals and total investments dollars peaked in 2015 with nearly $14 billion invested. As the authors highlighted, these global numbers were unsustainable and 2016 saw significant declines in both deals and dollars. In 2016, the total deals reported were 407 (21.6 percent decrease from 2015) and dollars invested was $6.4 billion (a 54.3 percent decrease from 2015).
On June 15, two startups based on Johns Hopkins technology received Incubator Company of the Year Awards at an annual event sponsored by the Maryland Technology Development Corporation (TEDCO) and several other organizations.
In Uganda alone, nearly 600,000 newborns require medical intervention for complications at birth. That’s a problem that Teresa Cauvel and Sona Shah are on a mission to solve. Neopenda, the health tech startup they founded in 2015, makes wearables that monitor four newborn vitals: Heart rate, respiration, blood oxygen saturation, and temperature.
Patients with active systemic lupus erythematosus (SLE) were able to control their disease with Benlysta (belimumab) plus standard of care (prednisone), pharmaceutical giant GSK said in announcing the results from a 10-year continuation study.
GSK presented the study’s results at the Annual European Congress of Rheumatology (EULAR 2017), held June 14-17 in Madrid.
New Enterprise Associates has closed its 16th flagship fund on $3.3 billion, per the Wall Street Journal, the largest venture vehicle ever raised.
A monumental fundraise, yes, but billion-dollar funds are nothing new for NEA—its latest vehicle also represents the firm’s seventh consecutive $1-billion-plus venture fund. In 1978, NEA closed its first fund on $16 million. The firm has gone on to garner $17 billion in committed capital across 15 funds, not including NEA 16. Here’s a look at the firm’s largest funds to date, according to the PitchBook Platform:
The University System of Maryland was ranked 27th by the National Academy of Inventors and the Intellectual Property Owners Association on a list of the most U.S. patents granted last year among universities worldwide.
The University of Maryland received 48 of the 72 patents granted to universities in the university system in 2016, said Felicia Metz, the intellectual property assistant director of this university’s Office of Technology Commercialization, which works with patents owned by the university and inventors to help make the products of research available on the market.
More and more, bwtech@UMBC has been a stop for international visitors looking to learn about cybersecurity, said executive director Ellen Hemmerly.
While paying a visit to the research park’s incubator or attending a conference offers a glimpse, there are signs of a desire to dig deeper. Earlier this year, the incubator was a “soft landing” for a group of companies from the Netherlands as part of an exchange program run by the Maryland Department of Commerce.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its fourth-generation HIV combination antigen-antibody assay, the Elecsys HIV combi PT assay, has received FDA PMA approval from the U.S. Food and Drug Administration (FDA).
Innovations born in the world of academia have contributed more than a trillion dollars to the US economy over the past two decades, according to a new report.
Examining the licensing of university technology, a study undertaken by the Biotechnology Innovation Organization (BIO) and the Association of University Technology Managers (AUTM), reveals that over a 20 year period ‘academic patents and the subsequent licensing to industry’ boosted industry output by $1.33 trillion.
University of Maryland, Baltimore County’s bwtech Research & Technology Park is partnering with the state Department of Commerce to create an international cybersecurity center that will help lure foreign cyber companies to establish a presence in Maryland.
Advances in biotechnology innovation have had an enormous transformative impact on many sectors of the U.S. economy — life-saving drugs for patients of all ages, protecting plants that are key to feeding the world and industrial biotechnology applications that are leading to bio-based fuels, chemicals and products that can protect our environment.
The bioscience’s need for a stable and supportive public policy framework is vital to industry firms large and small. It is almost impossible for any state or region to ignore the need for selective incentives to either hold existing bioscience companies or attract new enterprises.
Just as some politicians are increasing their calls for Washington micromanagement of the Bayh-Dole law (which allows universities and federal laboratories to license federally supported inventions for commercial development) a new study shows how impressively the current decentralized, market driven system is performing.
Despite the best cybersecurity efforts, the number of breaches in the healthcare world is remaining fairly constant, according to the latest Protenus Breach Barometer.
The Barometer is based on data provided by DataBreaches.net.
The Maryland Science Center has promoted from within to replace president and CEO Van Reiner, who will retire this year after 13 years with the Inner Harbor attraction.
Mark Potter, the organization’s vice president of development for the past six years, will assume the top spot following Reiner’s retirement in October.
Whether you’re a fan of Steve Jobs and his products or not, two things are undeniable: He was very successful and very different. Now you can relax; this short article will not provide a blow-by-blow account of the man and his methods. “What would Steve Jobs tell the pharma/biotech industry?” is just a metaphor to encourage our industry to radically change — not by reinventing the wheel, but by copying the success of others.
Here’s what New Enterprise Associates chief Scott Sandell says about his record fund, along with a look at the other 10 firms that have raised $1 billion or more since 2015.
Pharmaceutical companies are betting big on a new wave of innovative cancer therapies they believe will be more effective than existing treatments and move them a big step closer to finding a cure for the disease.
The fast-emerging branch of therapies – immuno-oncology (IO) – works by equipping the body’s immune system with the tools to kill cancer cells.
The Old Line’s flag laid board-flat against the marbled gray sky as crisply as if it had been pressed by a hot iron. I double checked my lifejacket, clipped the boat’s kill switch onto its nylon strap and eased the 25-foot center console beyond the breakwaters of Matapeake. White caps that had rolled past Point Lookout three hours earlier continued to barrel northward toward Rock Hall. I took a quick look around, briefly questioned my decision-making faculties and then punched the throttle to get on top of the rumbling three footers.
The Small Business Innovation Research and Small Business Technology Transfer Improvements Act of 2017, H.R. 2763, unanimously passed a House committee last week, moving one step closer to approval.
“The bill ultimately helps small businesses advance innovation and research that will help industries across California and the nation,” Knight said. “The advantages of supporting small business in their ventures are endless as some of the greatest entrepreneurial developments in technology originate from the support of the surrounding community and government resources.”
Nearly two years after its launch, Johnson & Johnson’s crowdfunding website for global public health projects in underserved communities has raised almost $500,000 for 51 projects to date.
The percentage of projects posted on the website that are funded has increased from 33 percent one year ago to 65 percent this year, according to an email from Fetzer.
Switzerland, Sweden, the Netherlands, U.S. and UK are the world’s most innovative countries according to a new report by produced by Cornell University, INSEAD and the World Intellectual Property Organization (WIPO).
Now in its 10 edition, the Global Innovation Index surveys 130 economies using dozens of metrics – from patent filings to education spending – for a high-level look at the innovative activity that increasingly drives economic and social growth.
The brain continues to surprise us with its magnificent complexity. Groundbreaking research that combines neuroscience with math tells us that our brain creates neural structures with up to 11 dimensions when it processes information. By “dimensions,” they mean abstract mathematical spaces, not other physical realms. Still, the researchers “found a world that we had never imagined,” said Henry Markram, director of the Blue Brain Project, which made the discovery.
Using an input-output “I-O” approach to estimating the economic impact of academic licensing and summing that impact over 20 years of available data for academic U.S. Association of University Technology Managers (AUTM) Survey respondents, the total contribution of these academic licensors to industry gross output ranges from $320 billion to $1.33 trillion, in 2009 U.S. dollars; and contributions to gross domestic product (GDP) range from $148 billion to $591 billion, in 2009 U.S. dollars. Estimates of the total number of person years of employment supported by U.S. universities’ and hospitals’ and research institutes’ licensed-product sales range from 1.268 million to over 4.272 million over the 20- year period. An explanation of the I-O approach is provided, and the assumptions used and the potential effects of the assumptions on the estimates are discussed. AUTM associated contributions to GDP, calculated using the I-O approach, are compared with U.S. GDP as a whole, and to selected industry, as defined by North American Industry Classification System (NAICS) codes, contributions to GDP. Factors affecting the AUTM contributions to GDP appear to differ from those affecting U.S. GDP as a whole, as well as from those affecting selected NAICS industry contributions to GDP.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
